Coherus Reveals US Launch Plans For Interchangeable Ranibizumab
Pricing Details Set Out Ahead Of 3 October Launch For Cimerli Biosimilar Version Of Lucentis
Coherus has revealed further details of the firm’s plans for its Cimerli interchangeable biosimilar rival to Lucentis in the US, including a launch date and pricing information.
